We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eisai Files for Full Approval of Alzheimer’s Drug Leqembi
Eisai Files for Full Approval of Alzheimer’s Drug Leqembi
On the heels of nabbing accelerated approval of its Alzheimer’s therapy Leqembi (lecanemab), Eisai has filed for full approval of the drug in patients with mild cognitive impairment (MCI) or mild dementia and confirmed presence of amyloid beta plaque in the brain.